Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Olaparib Could Be Re-Administered after Chemotherapy].

Gan to kagaku ryoho. Cancer & chemotherapy - 1 Apr 2023

Terasawa Risa, Takashima Yuko, Hirata Aoko, Kimura Kousei, Morita Shinsho, Hayashi Michihiro

Abstract excerpt

Olaparib, a PARP inhibitor, was approved in 2018 for BRCA1/2 gene mutation and HER2-negative inoperable or recurrent breast cancer with previous chemotherapy. Olaparib is an important drug with minor adverse events compared to chemotherapeutic drugs. In addition, it is expected to exert a high therapeutic effect on breast cancer with BRCA mutations due to its characteristics. We report a case of BRCA2-mutated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to BRCA1 Protein
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Ovarian Neoplasms

Source

Identifiers

PMID: 37066460

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Olaparib Could Be Re-Administered after Chemotherapy].PMID 37066460Read ↗

[Case of Recurrent Breast Cancer with BRCA2 Mutation Successfully Treated with Olaparib Therapy].Semantic proximity Read ↗

First PARP Inhibitor Ok'd for Breast CancerSemantic proximity Read ↗

Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 MutationSemantic proximity Read ↗

Olaparib for the treatment of breast cancer.Semantic proximity Read ↗

Real-world efficacy and toxicity of olaparib maintenance therapy in Korean ovarian cancer patients with an exploratory analysis of BRCA mutations.Semantic proximity Read ↗

[Effects of Olaparib, a PARP-1 Inhibitor, on Triple Negative Breast Cancer Cells with a BRCA1 Mutation].Semantic proximity Read ↗

[Olaparib in ovarian cancer with BRCA mutation].Semantic proximity Read ↗

Experiencia con el uso de olaparib en pacientes con cáncer de ovario.Semantic proximity Read ↗

Health-Related Quality of Life in PARP-Inhibitor Olaparib Maintenance in Ovarian Cancer Patients: Real World Data and Experience of a Single-Center in ChinaSemantic proximity Read ↗

The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.Semantic proximity Read ↗

Does early olaparib administration improve prognosis in patients with HER2-negative metastatic breast cancer and BRCA1 and/or BRCA2 pathogenic variants?: Finding from four casesSemantic proximity Read ↗

Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.